LOS ANGELES, July 2 /PRNewswire/ -- Vista Partners announced today that it
has updated coverage on leading Australian biotechnology company Arana
Therapeutics, (ASX: AAH; AIM: AAHx). "In our opinion, Arana differentiates
itself from many competitors in the biotech space due to a strong cash
position, a lucrative recurring revenue stream from IP licenses and a strong
internal portfolio of products and proprietary technology platform. We believe
Arana's lead anti-TNF domain-based antibody, ART621 is superior to any
antibody commercially available and should note that the three leading drugs
in the market combined for sales of US$12.8 billion in 2007, up 25% from the
previous year," said Ross Silver, Director of Research for Vista Partners. For
more information and to download the free report, please visit the Vista
Partners website at http://www.vistap.com and click on the "download research"
icon located in the top right hand corner of the website.
About Vista Partners:
Vista Partners provides independent, equity research to institutional and
individual investors, with a focus on publicly traded small capitalization
companies. With offices in Los Angeles and San Francisco, Vista Partners is
one of the fastest growing independently owned equity research firms. Vista
Partners professional staff has backgrounds in finance, corporate
communications and investment banking. More information is available at
http://www.vistap.com.
About Arana Therapeutics:
Arana Therapeutics (ASX: AAH) is an international biopharmaceutical
company formed through the merger of Peptech and EvoGenix in August 2007. The
company uses superior technology to develop next generation drugs that will
improve the lives of patients with inflammatory diseases and cancer.
Arana Therapeutics' innovative engineering technologies provide the basis
for clinical development in the antibody space, a market which draws on high
demand. Arana Therapeutics has the financial stability and management
expertise to accelerate its clinical programs, and is on track to have at
least 3 clinical stage assets within three years.
The pipeline consists of four lead drug programs: ART621 to treat severe
rheumatoid arthritis and other inflammatory diseases; ART010 to treat
osteoporosis and bone cancer; ART104 to treat solid tumours in colorectal
cancer; and ART150 for lung cancer and melanoma. Additionally the company has
earlier stage products in development for the treatment of a range of
conditions including age related macular degeneration, psoriasis, colorectal
cancer, and leukaemia.
Arana has recurring revenues from commercial and development partnerships
with six international companies including GSK, CSL, Centocor (J&J) and Abbott
Laboratories.
For further information: http://www.arana.com
Contact:
Vista Partners LLC
Sherry Watkins
(310) 744-5268
info@vistap.com
http://www.vistap.com
SOURCE Vista Partners
Sherry Watkins, +1-310-744-5268, info@vistap.com
